Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

GERMANTOWN, Md., Jan. 30 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has closed its previously announced private placement of common stock and warrants, resulting in the receipt of $21 million in gross proceeds.

The Company intends to use the proceeds from the financing to support the manufacture of MOXATAG(TM), its once-daily amoxicillin product, and for working capital and general corporate purposes.

The shares sold in the private placement and the shares issuable upon the exercise of the related warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission ("SEC") or through an applicable exemption from SEC registration requirements. The shares and warrants were offered and sold only to institutional and accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the common stock issued in the private placement and issuable upon the exercise of the warrants.

This news release is not an offer to sell or the solicitation of an offer to buy the shares of the Company.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercial
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis ... been reached with Switzerland -based ... anti-infective human monoclonal antibody (mAb) products, and technologies. ... mAb products for treatment of infections by common ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
(Date:5/17/2013)... RURO Inc. is pleased to ... versatile refinement to the smart management solution. , ... advanced methodical management for transgenic animal colonies, genotyping ... network-based platform provides user access with a plethora ... to emphasize streamlined tasks, such as animal relocation ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... VIENNA, Va., March 10 CEL-SCI Corporation (NYSE Alternext ... to launch a new manufacturing process that could allow ... to maintain their potency and thereby potentially also their ... developed by CEL-SCI may also significantly accelerate the time ...
... Take Market Share Away from Lucentis from 2012 ... Decision ResourcesWALTHAM, Mass., March 10 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that ... macular degeneration (AMD) market through 2012 will be ...
... Tolerx, Inc., today announced that DEFEND ( D urable ... arly or N ew Onset Type 1 D ... targeted immunotherapeutic, has begun enrollment of new onset autoimmune type ... cell function subsequent to the administration of otelixizumab is the ...
Cached Biology Technology:CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 2Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe 3Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe 2Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe 3Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe 4
(Date:5/16/2013)... predict the stability of today,s largest ice sheets in Greenland ... years ago, for example when Earth was going through ... a high sea level due to ice sheet collapse at ... that if the world,s largest ice sheets collapsed in the ... modern, progressively warming world. , However, a new groundbreaking ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
(Date:5/16/2013)... , May 16, 2013 Integrated ... combination with a custom thin film transistor camera ... forensic quality roll image in the smallest and ... Sherlock, an Appendix F Mobile ID FAP 45, ... 95% reduction in size and weight when compared ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... the first time, scientists have described not only the identities ... in this case, a mouse macrophage or white blood ... and change over time to a bacterial stimulus triggering the ... of the Journal of Biological Chemistry , lead author ...
... of time, the colonial hydrology of the northeastern U.S. has ... social scientists. The results, which extend as far back ... the journal Environmental Science & Technology (ES&T). ... of the past, and will lead to a better understanding ...
... / ST. PAUL (December 1, 2010) University of ... is among an international group of researchers that has ... of sexual maturation in women. Many of these genes ... energy metabolism. Prior to the multi-institutional study, only four ...
Cached Biology News:Researchers describe first functioning 'lipidome' of mouse macrophage 2Researchers describe first functioning 'lipidome' of mouse macrophage 3America's colonial hydrologic history recreated 2U of M researcher helps unlock 30 new genes responsible for early onset puberty 2
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
Request Info...
Request Info...
Biology Products: